Longeveron stem cell trial fails, biotech weighs options
A phase 2b miss in a pediatric heart condition pushes the cash-strapped company to cut costs and reconsider its future.
Longeveron's experimental stem cell therapy for a pediatric heart disease failed its phase 2b trial, missing the main goal of the study. The company, which had limited cash reserves, now says it will examine every possible path forward, including a sale, merger, or other restructuring.
In the wake of the setback, Longeveron plans to reduce spending and explore "all options" for the business, according to the company's announcement. The trial's failure is a significant blow to the therapy's development, and the financial strain is likely to accelerate the need for a strategic decision.
No other sources were provided, so this report relies solely on the Fierce Biotech article. The company has not yet disclosed detailed efficacy or safety data from the trial, and the specific timeline for its strategic review remains unclear.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.